Keryx Biopharmaceuticals Inc
KERX
KERX was delisted on the 12th of December, 2018.
131 hedge funds and large institutions have $283M invested in Keryx Biopharmaceuticals Inc in 2018 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 38 increasing their positions, 32 reducing their positions, and 15 closing their positions.
40% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 15
19% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 32
5% more funds holding
Funds holding: 125 → 131 (+6)
0% less call options, than puts
Call options by funds: $2.21M | Put options by funds: $2.22M
1.69% less ownership
Funds ownership: 64.22% → 62.53% (-1.7%)
10% less capital invested
Capital invested by funds: $313M → $283M (-$30M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PIMJS
PKO Investment Management Joint-Stock
Warsaw,
Poland
|
+$7.16M |
| 2 |
Morgan Stanley
New York
|
+$3.76M |
| 3 |
BlackRock
New York
|
+$2.6M |
| 4 |
OWIM
Old West Investment Management
Los Angeles,
California
|
+$2.16M |
| 5 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
+$1.76M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CLM
ClearBridge LLC (Maryland)
Baltimore,
Maryland
|
-$5.83M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.49M |
| 3 |
State Street
Boston,
Massachusetts
|
-$4.93M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$3.95M |
| 5 |
Goldman Sachs
New York
|
-$3.52M |
KERX Hedge Fund Activity: Q2 2018 in Review
131 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Keryx Biopharmaceuticals Inc (KERX) for Q2 2018, worth a combined $283M — down 9.6% from $313M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new KERX positions and 15 closed out — a net gain of 6 holders — while 38 added to existing stakes and 32 trimmed.
The largest buyer was PKO Investment Management Joint-Stock, opening a new position worth an estimated $7.16M. The largest seller was ClearBridge LLC (Maryland), cutting an estimated $5.83M.
- 131 institutional investors held Keryx Biopharmaceuticals Inc (KERX) as of Q2 2018, up from 125 in Q1 2018.
- Funds reported $283M of Keryx Biopharmaceuticals Inc stock for Q2 2018, down 9.6% quarter-over-quarter.
- 21 funds opened new Keryx Biopharmaceuticals Inc positions in Q2 2018 and 15 closed out, a net change of +6 holders.
- The largest Keryx Biopharmaceuticals Inc buyer in Q2 2018 was PKO Investment Management Joint-Stock, an estimated $7.16M added.
- The largest Keryx Biopharmaceuticals Inc seller in Q2 2018 was ClearBridge LLC (Maryland), an estimated $5.83M sold.
Based on aggregated 13F filings for Q2 2018.